Table of Contents

2019-2024 Global Amifostine Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Amifostine Consumption 2014-2024
  • 2.1.2 Amifostine Consumption CAGR by Region
• 2.2 Amifostine Segment by Type
  • 2.2.1 400mg/Dose
  • 2.2.2 500mg/Dose
• 2.3 Amifostine Consumption by Type
  • 2.3.1 Global Amifostine Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Amifostine Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Amifostine Sale Price by Type (2014-2019)
• 2.4 Amifostine Segment by Application
  • 2.4.1 Head and Neck Cancer Adjuvant Therapy
  • 2.4.2 Others
• 2.5 Amifostine Consumption by Application
  • 2.5.1 Global Amifostine Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Amifostine Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Amifostine Sale Price by Application (2014-2019)

3 Global Amifostine by Players

• 3.1 Global Amifostine Sales Market Share by Players
  • 3.1.1 Global Amifostine Sales by Players (2017-2019)
  • 3.1.2 Global Amifostine Sales Market Share by Players (2017-2019)
• 3.2 Global Amifostine Revenue Market Share by Players
  • 3.2.1 Global Amifostine Revenue by Players (2017-2019)
  • 3.2.2 Global Amifostine Revenue Market Share by Players (2017-2019)
• 3.3 Global Amifostine Sale Price by Players
• 3.4 Global Amifostine Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global Amifostine Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players Amifostine Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Amifostine by Regions

• 4.1 Amifostine by Regions
  • 4.1.1 Global Amifostine Consumption by Regions
  • 4.1.2 Global Amifostine Value by Regions
• 4.2 Americas Amifostine Consumption Growth
• 4.3 APAC Amifostine Consumption Growth
• 4.4 Europe Amifostine Consumption Growth
• 4.5 Middle East & Africa Amifostine Consumption Growth

5 Americas

• 5.1 Americas Amifostine Consumption by Countries
  • 5.1.1 Americas Amifostine Consumption by Countries (2014-2019)
  • 5.1.2 Americas Amifostine Value by Countries (2014-2019)
• 5.2 Americas Amifostine Consumption by Type
• 5.3 Americas Amifostine Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Amifostine Consumption by Countries
  • 6.1.1 APAC Amifostine Consumption by Countries (2014-2019)
  • 6.1.2 APAC Amifostine Value by Countries (2014-2019)
• 6.2 APAC Amifostine Consumption by Type
• 6.3 APAC Amifostine Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Amifostine by Countries
  • 7.1.1 Europe Amifostine Consumption by Countries (2014-2019)
  • 7.1.2 Europe Amifostine Value by Countries (2014-2019)
• 7.2 Europe Amifostine Consumption by Type
• 7.3 Europe Amifostine Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Amifostine by Countries
  • 8.1.1 Middle East & Africa Amifostine Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Amifostine Value by Countries (2014-2019)
• 8.2 Middle East & Africa Amifostine Consumption by Type
• 8.3 Middle East & Africa Amifostine Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Amifostine Distributors
• 10.3 Amifostine Customer

11 Global Amifostine Market Forecast

• 11.1 Global Amifostine Consumption Forecast (2019-2024)
• 11.2 Global Amifostine Forecast by Regions
  • 11.2.1 Global Amifostine Forecast by Regions (2019-2024)
  • 11.2.2 Global Amifostine Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Amifostine Forecast by Type
• 11.8 Global Amifostine Forecast by Application

12 Key Players Analysis

• 12.1 Clinigen Group
  • 12.1.1 Company Details
  • 12.1.2 Amifostine Product Offered
  • 12.1.3 Clinigen Group Amifostine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 Clinigen Group News
• 12.2 Sun Pharmaceutical
  • 12.2.1 Company Details
  • 12.2.2 Amifostine Product Offered
  • 12.2.3 Sun Pharmaceutical Amifostine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Sun Pharmaceutical News
• 12.3 Taj Pharmaceuticals
  • 12.3.1 Company Details
  • 12.3.2 Amifostine Product Offered
  • 12.3.3 Taj Pharmaceuticals Amifostine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Taj Pharmaceuticals News
• 12.4 Merro Pharmaceutical
  • 12.4.1 Company Details
  • 12.4.2 Amifostine Product Offered
  • 12.4.3 Merro Pharmaceutical Amifostine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 Merro Pharmaceutical News
• 12.5 Luye Pharma
  • 12.5.1 Company Details
  • 12.5.2 Amifostine Product Offered
  • 12.5.3 Luye Pharma Amifostine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 Luye Pharma News
• 12.6 Mingren Pharma
  • 12.6.1 Company Details
  • 12.6.2 Amifostine Product Offered
  • 12.6.3 Mingren Pharma Amifostine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Mingren Pharma News

...

13 Research Findings and Conclusion

Amifostine (Ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed by Clinigen Group under the trade name Ethyol.
Amifostine is a pro-drug which is activated to the free thiol metabolite at the tissue site. The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells.

Consumption of amifostine mainly concentrates in North America. In 2016, the region consumed 780 K Unit, holding about 52% market share globally. The follower is Asia-Pacific, with about 41% consumption share.

The market is relatively concentrated and there are just a few suppliers in the market, such as Clinigen Group, Sun Pharmaceutical, Merro Pharmaceutical and so on. Clinigen Group acquired the business from AstraZeneca in the year of 2014 and signed an agreement with Cumberland in the year of 2016. Under the agreement, Cumberland acquired the exclusive rights to commercialize Ethyol in the United States. Merro Pharmaceutical own the largest sales share in China.

Amifostine shows good effect in reducing harmful effects of cisplatin chemotherapy on kidneys in women treated for advanced ovarian cancer as well as relieving dry mouth problems (xerostomia) with head and neck cancer patients undergoing radiation treatment. It is estimated that the amifostine market will keep upward tendency and to be worthy of 49.99 million USD in 2023 globally.

According to this study, over the next five years the Amifostine market will register a 2.1% CAGR in terms of revenue, the global market size will reach US$ 54 million by 2024, from US$ 48 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Amifostine business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Amifostine market by product type, application, key manufacturers and key regions and countries.

This study considers the Amifostine value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
400mg/Dose
500mg/Dose
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Head and Neck Cancer Adjuvant Therapy
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Clinigen Group
Sun Pharmaceutical
Taj Pharmaceuticals
Merro Pharmaceutical
Luye Pharma
Mingren Pharma
...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Amifostine consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Amifostine market by identifying its various subsegments.
Focuses on the key global Amifostine manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amifostine with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Amifostine submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.